From this page You could reach all the figures at the Turkish Journal of Hematology archive.
You could save all the imges by the save as button and paste them to office documents.
Please use the articles details for reference.
You could see the abstracts of the images from the link above the image.
Search In Pictures
Search In Articles
Not null!
Search term(s) must be at least 3 characters!
All Types
Microscope display
FISH display
(MDCT),MRI,radiologic
Dermatologic
Other
6 records found...
Anticoagulation (ECAA): Studies on Computer-Assisted Anticoagulant Dosage
Figure 1. Percentage time in all INR ranges (Rosendaal).
Anticoagulation (ECAA): Studies on Computer-Assisted Anticoagulant Dosage
Figure 2. Dawn AC participants.
Anticoagulation (ECAA): Studies on Computer-Assisted Anticoagulant Dosage
Figure 3. Parma participants.
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux
Figure 1. The Choay Group: Maurice Petitou (left), Jean Choay (center) and Jean-Claude Lormeau (right) which undertook the development of the pentasaccharide as antithrombotic drug
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux
Figure 2. Fondaparinux (pentasaccharide; Org31540/SR90107A; Arixtra®; Sanofi-Synthélabo/Organon) is composed of the specific sequence of saccharide units required for heparin binding to AT and expression of a strong antifactor Xa activity. Based on the data from four phase III clinical trials, the US FDA and the European CPMP have approved fondaparinux for the prophylaxis of deep venous thrombosis in patients undergoing surgery for hip fracture, hip replacement and knee replacement. Trials are in progress for other clinical indications.
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux
Figure 3. Dose-response of fondaparinux in the chromogenic antifactor Xa assay. The specific structure of fondaparinux that allows binding to AT is critical for expression of the anti-FXa activity as shown by the loss of activity by a pentasaccharide of the same structure but without the 3-O sulfate group on the F unit.
1
Sayfa 1 / 1 -- Toplam Kayıt 6 -- Listelenen kayıt sayısı 6
Not null!
Search term(s) must be at least 3 characters!
All Columns
Referance Numbers
Titles
Summeries
Keywords
0 records found...
1
Sayfa 1 / 1 -- Toplam Kayıt 0 -- Listelenen kayıt sayısı 0
AUTOIMMUNE DISORDERS (0 / 0)
Autoimmune Hemolytic Anemias (0 / 0)
Others (0 / 0)
CHEMOKINES (0 / 8)
Chemokines and cytokines (0 / 0)
Chemotactic Effects (0 / 2)
Other Effects (0 / 0)
Hematopoietic (0 / 0)
Angiogenic (0 / 0)
HIV Effects (0 / 6)
Regulation of Receptor Expression (0 / 0)
Signal Transduction (0 / 0)
CYTOGENETICS (0 / 2)
Gene Polymorphisms (0 / 2)
HEMOSTASIS (0 / 87)
Platelet and the vessel wall (0 / 13)
Blood coagulation (0 / 24)
Biology of hemostatic proteins (0 / 4)
Fibrinogen (0 / 0)
Vitamin K-dependent coagulation factors (0 / 0)
Coagulation factors (0 / 4)
Factor VIII-Factor IX-Factor XI (0 / 8)
Other coagulation factors (0 / 0)
Protein C anticoagulant pathway (0 / 0)
Other coagulation inhibitors (0 / 0)
Fibrinolytic enzymes and inhibitors (0 / 0)
Thrombotic Disorders (0 / 36)
Inherited coagulopathies (0 / 4)
Antithrombin deficiency (0 / 0)
Protein C deficiency (0 / 4)
Protein S deficiency (0 / 0)
Factor V Leiden mutation (0 / 0)
Prothrombin t20210A Mutation (0 / 0)
Acquired coagulation disorders (0 / 5)
Disseminated intravascular coagulation (0 / 5)
Liver Disease (0 / 0)
Vitamin K Deficiency (0 / 0)
Massive Transfusion Coagulapathies (0 / 0)
Acquired Inhibitors of coagulation proteins (0 / 0)
Replacement therapies (0 / 0)
Other therapies (0 / 0)
Cancer and thrombosis (0 / 3)
Antiphospholipid antibody syndrome (0 / 1)
Thrombotic thrombocytopenic purpura (0 / 1)
Heparin-induced thrombocytopenia (0 / 0)
Venous thromboembolism treatment (0 / 0)
Arterial thrombosis (0 / 13)
Antithrombotic therapy (0 / 6)
Heparin, low molecular weight heparin (0 / 3)
Direct thrombin inhibitors (0 / 0)
Oral anticoagulants (0 / 3)
Antifibrinolytic therapy (0 / 0)
Endothelium (0 / 1)
HEMATOLOGİC MANIFESTATİONS OF SYSTEMİC DISEASES (0 / 46)
GENE THERAPY (0 / 0)
HEMATOPOIESIS (0 / 8)
Stem and Primitive Progenitor Cells (0 / 0)
Red Blood Cells (0 / 0)
Granulocytes (0 / 1)
Lymphocytes (0 / 3)
Monocytes (0 / 0)
Eosinophilia (0 / 1)
Basophilia (0 / 0)
Megakaryocytes (0 / 3)
Mast Cells (0 / 0)
IRON (0 / 13)
Iron Deficiency (0 / 10)
Iron Overload (0 / 3)
IMMUNOLOGY (0 / 22)
Innate Immunity (0 / 0)
Immunoglobulins (0 / 16)
Antigen Recognition by T Lymphocytes (0 / 0)
The Development of B Lymphocytes (0 / 0)
T-Cell Mediated Immunity (0 / 0)
The Humoral Immune Response (0 / 0)
Immundeficiency dieases (0 / 0)
Allergy and Hypersensitivity (0 / 3)
Immune Response Disorder (0 / 3)
Autoimmunity: responses to self antigens (0 / 2)
Transplant rejection: responses to alloantigens (0 / 0)
Tumor immunology (0 / 0)
Lymphoid Cells Neoplasms (0 / 0)
B-cell neoplasms (0 / 0)
T-cell neoplasms (0 / 0)
NK cell neoplasms (0 / 0)
Others (0 / 0)
INFECTION (0 / 16)
Febril Neutropenia (0 / 6)
Viral Infections (0 / 1)
Fungan Infections (0 / 1)
Bacterial Infections (0 / 2)
Parasitic Infections (0 / 2)
MARROW (0 / 9)
Physiology of Hematopoiesis (0 / 5)
Bone Marrow Failure (0 / 1)
Acquired Aplastic Anemia (0 / 3)
Fanconi Anemia (0 / 0)
Inherited Pure Red Cell Anemia (0 / 0)
Acquired Pure Red Cell Anemia (0 / 0)
STEM CELL TRANSPLANTATION (0 / 54)
Stem cell physiology (0 / 9)
Stem cell mobilization (0 / 0)
Immunologic tolerance (0 / 0)
Graft rejection (0 / 0)
Conditioning regimen (0 / 0)
Allo transplantation (0 / 18)
Auto transplantation (0 / 2)
Non myeloablative (0 / 0)
Organ Specific Toxicity (0 / 3)
Clinical Care of Graft-Versus-Host Disease (0 / 10)
Acute GVHD (0 / 0)
Chronic GVHD (0 / 10)
NEOPLASIA (0 / 354)
Pediatric hematologic Malignancies (0 / 3)
Pediatric Leukemia (0 / 8)
Pediatric Lymphomas (0 / 2)
Acute Leukemia (0 / 12)
Acute Lymphoblastic Leukemia (0 / 36)
Acute Myeloblastic Leukemia (0 / 66)
Myelodysplastic Syndromes (0 / 3)
Chronic Leukemia (0 / 0)
Chronic Lymphocytic Leukemia (0 / 7)
Chronic Myeloid Leukemia (0 / 18)
Other Lymphoproliferative Disorders (0 / 2)
Other Leukemias (0 / 12)
Lymphomas (0 / 37)
Hodgkin Lymphoma (0 / 10)
Non Hodgkin Lymphoma (0 / 45)
Chronic Myeloproliferative Neoplasms (0 / 32)
Pharmacotherapeutics (0 / 3)
Oncogenes (0 / 0)
Multipl myeloma (0 / 45)
Plasmacytoma (0 / 2)
Cryoglobulinemia (0 / 2)
Plasma Cell Disorders (0 / 7)
PHAGOCYTES (0 / 16)
Neutrophils (0 / 4)
Monocytes and Macrophages (0 / 3)
Eosinophils (0 / 3)
Basophils (0 / 0)
Mast cells (0 / 0)
Dendritic cells (0 / 6)
Chemotaxis (0 / 0)
Antigen presentation (0 / 0)
Phagocytosis, cytotoxicity (0 / 2)
PLATELETS (0 / 34)
Physiology of Normal Platelets (0 / 10)
Signal Transduction (0 / 0)
Disorders of Platelets (0 / 12)
von Willebrand Disease (0 / 7)
Acquired Platelet Disorders (0 / 0)
Autoimmune and Alloimmune platelet disorders (0 / 2)
RED CELLS (2 / 92)
Hemoglobin disorders (0 / 6)
Anemia (2 / 40)
Nutritional anemia (0 / 9)
iron, cobalamin, folate deficiency (0 / 7)
Fanconi Anemia (0 / 1)
Aplastic Anemia (0 / 6)
Myeloproliferative and myelodysplasia (0 / 0)
Immune Hemolytic anemias (2 / 12)
Red cell membrane disorders (0 / 7)
Paroxymal Nocturnal hemoglobin (PNH) (0 / 0)
Enzyme disorders (0 / 0)
Sickle cell anemia (0 / 4)
Thalassemia (0 / 19)
Other hemoglobinopathies (0 / 11)
Polycythemia (0 / 4)
Polycythemia Vera (0 / 3)
Secondary Polycythemia (0 / 0)
WHITE CELLS (0 / 4)
Congenital Neutropenia (0 / 3)
Acquired Neutropenia (0 / 0)
Leucocyte Function Disorders (0 / 0)
Lymphocytes (0 / 0)
SUPPORTIVE CARE (0 / 0)
MOLECULAR HEMATOLOGY (0 / 6)
TRANSFUSION MEDICINE (0 / 10)
Apheresis (0 / 4)
Red Blood Cells (0 / 3)
White cell transfusions (0 / 1)
Platelet transfusions (0 / 0)
VASCULAR BIOLOGY (0 / 0)
OTHER (325 / 85)
FLOW CYTOMETRY (0 / 2)
STORAGE DISORDERS (0 / 14)
Spleen (0 / 1)
Experimental Hematology (0 / 3)
IRRADIATION (0 / 3)
Copyright © 2024 Atlas of Hematology. All rights reserved.
LookUs
&
OnlineMakale